Aspergillus infections

1		Impact of Pre-existing Invasive Aspergillosis on Allogeneic Stem Cell Transplantation	Invasive Aspergillosis		Observational Model: Case-Control Time Perspective: Prospective	Charité Universitätsmedizin Berlin Berlin, Germany Institute G. Gaslini Genova, Italy Clinica di Oncoematologia Pediatrica Padova, Italy (and 5 more...)
2		Novel Biomarkers for Invasive Aspergillosis	Aspergillosis Invasive	Procedure: blood sample	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Diagnostic	University Hospitals Leuven Leuven, Belgium
3		Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on InvasiveAspergillosis	Invasive Aspergillosis	Drug: Micafungin	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Beijing, China Changsha, China Chengdu, China (and 16 more...)
4		Clinical Implications of Azole-Resistant Aspergillosisin Hematological Malignancy	Invasive Aspergillosis	Other: Registry	Observational Model: Case-Only Time Perspective: Prospective	University Hospital of Cologne Cologne, NRW, Germany Radboud University Nijmegen Medical Center Nijmegen, Netherlands
5		Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)	Aspergillosis	Drug: voriconazole Drug: anidulafungin	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Pfizer Investigational Site Atlanta, Georgia, United States Pfizer Investigational Site Detroit, Michigan, United States Pfizer Investigational Site Fort Worth, Texas, United States Pfizer Investigational Site Fort Worth, Texas, United States
6		Galactomannan Antigen in Bronchoalveolar Lavage in the Diagnosis of Invasive Aspergillosis in Neutropenic Patients	Invasive Aspergillosis		Observational Model: Case Control Time Perspective: Prospective	Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau Barcelona, Spain
7		A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).	Aspergillosis	Drug: Anidulafungin, VER002	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Versicor, Inc. King of Prussia, Pennsylvania, United States
8		Prospective Multicenter Evaluation of the MycoGenie Kit for the Diagnosis of Invasive Aspergillosis	Invasive Aspergillosisin Patients With Onco-haematological Diseases	Diagnostic Test: DNA extraction and detection of Aspergillus fumigatus in serum samples	Observational Model: Cohort Time Perspective: Prospective	CHU Bordeaux, Groupe hospitalier Bordeaux, France CHU de DIJON, Hôpital du bocage Dijon, France CHRU de Lille, Hôpital Claude Huriez Lille, France (and 3 more...)
9		Exhaled Breath Analysis in the Early Detection ofAspergillosis	Invasive Aspergillosis		Observational Model: Cohort Time Perspective: Prospective	Academic Medical Center Amsterdam, Netherlands University Medical Center Utrecht Utrecht, Netherlands
10		Correlation Between Circulating Galactomannan and Beta-D-glucan and Clinical Outcome of InvasiveAspergillosis	Invasive Aspergillosis		Observational Model: Cohort Time Perspective: Retrospective
11		Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis	Invasive Aspergillosis	Drug: caspofungin	Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	University Hospital Gasthuisberg Leuven, Belgium Charité - Campus Benjamin Franklin Berlin, Germany Klinikum der Universität zu Köln Köln, Germany Universitätsklinikum Münster Münster, Germany
12		Study to Evaluate the Safety and Efficacy of the Combination Therapy of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive PulmonaryAspergillosis	Invasive Pulmonary Aspergillosis	Drug: SCY-078 Drug: Voriconazole Other: Oral Placebo Tablets	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment	Memorial Hermann Hospital Texas Medical Center Clinical Research Unit Houston, Texas, United States
13		Chronic Pulmonary Aspergillosis and Ambisome Aerosol With Itraconazole	Chronic Pulmonary Aspergillosis	Drug: inhaled Ambisome® Drug: inhaled placebo Drug: Itraconazole	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Participant) Primary Purpose: Treatment	CHU Grenoble Grenoble, France
14		Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis	Aspergillosis	Drug: Voriconazole, micafungin	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment	UAMS Little Rock, Arkansas, United States University of Arkansas Little Rock, Arkansas, United States
15		Diagnosing Pulmonary Aspergillosis in Patients With Hematological Malignancies: A Multicentre Prospective Evaluation of an Aspergillus PCR Assay and a Galactomannan ELISA in Bronchoalveolar Lavage Samples	Invasive Aspergillosis		Observational Model: Case Control Time Perspective: Prospective	Innsbruck University Hospital Innsbruck, Austria Cologne University Hospital Cologne, Germany Erlangen University Hospital Erlangen, Germany (and 6 more...)
16		Micafungin Salvage Mono-therapy in InvasiveAspergillosis	Invasive Aspergillosis	Drug: Micafungin Drug: Systemic antifungal therapy	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	Buenos Aires, Argentina La Plata, Argentina Aalst, Belgium (and 45 more...)
17		A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children	Invasive Aspergillosis	Drug: Voriconazole	Allocation: Non-Randomized Masking: None (Open Label) Primary Purpose: Treatment	Childrens Hospital Los Angeles Los Angeles, California, United States Children's Hospital & Research Center Oakland (CHRCO) Oakland, California, United States Children's Hospital of Pittsburgh of UPMC Pittsburgh, Pennsylvania, United States (and 22 more...)
18		Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis	Aspergillosis	Drug: nebulised liposomal amphotericin B	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Prevention	Erasmus MC centrumlocatie Rotterdam, Netherlands Erasmus MC locatie Daniel den Hoed Rotterdam, Netherlands
19		Diagnosing Invasive Aspergillosis by Polymerase Chain Reaction (PCR) Based Investigation of Bronchoalveolar Lavage Samples During Antifungal Therapy	Invasive Aspergillosis		Observational Model: Case Control Time Perspective: Retrospective	Innsbruck University Hospital Innsbruck, Austria Bielefeld evangelisches Krankenhaus Bielefeld, Germany Bochum University Hospital Bochum, Germany (and 19 more...)
20		Aspergillus-specific IgG Assays for the Diagnosis of Chronic Pulmonary Aspergillosis (CPA)-Multicenter Study	Chronic Pulmonary Aspergillosis		Observational Model: Cohort Time Perspective: Prospective	301 PLA general hospital BeiJing, Beijing, China
21		MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage InvasiveAspergillosis (0991-037)	Aspergillosis	Drug: MK0991, caspofungin acetate Drug: Comparator: amphotericin B Drug: Comparator: lipid formulation of amphotericin B and/or azole	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment
22		Application of an Electronic Nose in the Early Detection of ASpergillosis	Pulmonary Invasive Aspergillosis		Observational Model: Cohort Time Perspective: Prospective	Department of Hematology, Academic Medical Center Amsterdam, Netherlands
23		Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis	Aspergillosis	Drug: voriconazole Drug: anidulafungin	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment	Pfizer Investigational Site Birmingham, Alabama, United States Pfizer Investigational Site Birmingham, Alabama, United States Pfizer Investigational Site Little Rock, Arkansas, United States (and 104 more...)
24		Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) forAspergillosis	Aspergillosis	Drug: Micafungin Drug: Liposomal Amphotericin B	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Washington, District of Columbia, United States Atlanta, Georgia, United States Ann Arbor, Michigan, United States (and 4 more...)
25		Voriconazole For Chronic BronchopulmonaryAspergillosis	Aspergillosis	Drug: Voriconazole	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Pfizer Investigational Site Nantes, Cedex, France Pfizer Investigational Site Angers Cedex, France Pfizer Investigational Site Bobigny, France (and 15 more...)
26		Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis	Allergic Bronchopulmonary Aspergillosis	Drug: Glucocorticoids	Allocation: Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Postgraduate Institute of Medical Education and Research Chandigarh, India
27		Diagnostic Value of MRI for Allergic Broncho-Pulmonary Aspergilloses	Allergic Bronchopulmonary Aspergilloses	Device: MRI Device: CT scan (standard reference)	Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Diagnostic	CHU de Bordeaux Pessac, France
28		A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for InvasiveAspergillosis	Aspergillosis/Blood Aspergillosis/Invasive	Drug: micafungin Drug: voriconazole	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Treatment	Birmingham, Alabama, United States Fountain Valley, California, United States Los Angeles, California, United States (and 41 more...)
29		A Study Evaluating Vitamin D in Allergic Bronchopulmonary Aspergillosis Complicating Asthma	Allergic Bronchopulmonary Aspergilloses	Drug: Glucocorticoids Drug: Vitamin D	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	Postgraduate Institute of Medical Education and Research Chandigarh, India
30		Efficacy Of Itraconazole In Chronic Cavitary Pulmonary Aspergillosis	Chronic Cavitary Pulmonary Aspergillosis	Drug: Itraconazole Drug: treatment in cavitary pulmonary aspergillosis	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	PGIMER Chandigarh, Punjab, India
31		VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults	Invasive Aspergillosis Invasive Pulmonary Aspergillosis	Drug: Investigational Agent: VL-2397 Drug: Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Outcomes Assessor) Primary Purpose: Treatment	University of Alabama at Birmingham Hospital, Division of Infectious Diseases Birmingham, Alabama, United States UC San Diego Moores Cancer Center La Jolla, California, United States UC Davis Health, Dept. of Internal Medicine, Div. of Infectious Diseases Sacramento, California, United States (and 25 more...)
32		Study of FK463 for the Treatment of InvasiveAspergillosis	Aspergillosis	Drug: FK463	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Medizinische Univ.-Klinik Graz, Austria Krankenhaus Elisabethinen Linz Linz, Austria Hopital Henri Mondor, Service d'Hematologie Clinique Creteil, France (and 20 more...)
33		A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis	Allergic Bronchopulmonary Aspergillosis	Drug: Itraconazole Drug: Glucocorticoids	Allocation: Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Chest Clinic, PGIMER Chandigarh, India
34		Bronchoalveolar Lavage Lateral-Flow Device Test for Invasive Pulmonary Aspergillosis: a Multicenter Study	Invasive Pulmonary Aspergillosis	Device: Lateral Flow Device Test	Observational Model: Cohort Time Perspective: Prospective	Medical university of Graz Graz, Austria Innsbruck medical University Innsbruck, Austria Medical University of Vienna Vienna, Austria University Hospital Mannheim Mannheim, Germany
35		PET/CT Guided Antifungal Stewardship in Invasive Pulmonary Aspergillosis	Aspergillosis and Haematological Malignancy	Device: imaging 18F-FDG-PET/CT Biological: Blood collection	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Other	Department of Infectious Diseases and Tropical Medicine, Necker enfants malades hospital Paris, France
36		COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of InvasiveAspergillosis	Invasive Aspergillosis	Drug: Ambisome Drug: caspofungin	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	Gilead Sciences Paris, France
37		A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of InvasiveAspergillosis in High-risk Haematology Patients	Invasive Aspergillosis	Other: Culture and histology Other: Aspergillus galactomannan and PCR	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Diagnostic	St. Vincent's Hospital Sydney, New South Wales, Australia Westmead Hospital Sydney, New South Wales, Australia Royal Adelaide Hospital Adelaide, South Australia, Australia (and 3 more...)
38		Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary Aspergillosis	Allergic Bronchopulmonary Aspergillosis	Drug: Prednisolone Drug: Voriconazole	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	Postgraduate Institute of Medical Education and Research Chandigarh, India
39		Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)	Hematological Diseases Invasive Aspergillosis		Observational Model: Cohort Time Perspective: Prospective	Azienda Sanitaria Ospedaliera santa Croce e Carle Cuneo, Italy
40		Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill Patients	Aspergillosis; Pulmonary, Invasive (Etiology)	Drug: SOC +Posaconazole 18 MG/ML (milligram/milliliter) Other: standard of care (SOC)	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Prevention	AZ Sint Jan Brugge, Belgium UZ Gent Gent, Belgium UZ Leuven Leuven, Belgium (and 4 more...)
41		Aspergillus-specific PCR Assay in Cerebrospinal Fluid Samples for Detection of Central Nervous SystemAspergillosis	Aspergillosis Infection in an Immunocompromised Host		Observational Model: Cohort Time Perspective: Retrospective	Mannheim University Hospital Mannheim, Germany
42		Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic BronchopulmonaryAspergillosis (Cystic Fibrosis Excluded).	Allergic Bronchopulmonary Aspergillosis	Drug: Liposomal amphotericin B (Ambisome®) Drug: placebo	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Participant) Primary Purpose: Treatment	Chu de Poitiers Poitiers, France
43		Six Months Versus 12 Months of Oral Itraconazole Therapy for Management of Treatment naïve Subjects With CPA	Chronic Pulmonary Aspergillosis	Drug: Itraconazole 400 mg	Allocation: Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Inderpaul Singh Chandigarh, India
44		An Evaluation of Sequential Computed Tomography of the Chest in Management of Invasive PulmonalAspergillosis in Neutropenic Patients With Haematological Malignancies	Invasive Aspergillosis		Observational Model: Cohort Time Perspective: Retrospective	University Hospital of Cologne Cologne, North Rhine-Westphalia, Germany
45		Evaluation of Exhaled Breath Condensate in the Diagnosis of Invasive Pulmonary Aspergillosis	Invasive Pulmonary Aspergillosis		Time Perspective: Prospective	UZ Leuven Leuven, Belgium
46		An Observational Study of Fungal Biomarkers (MK-0000-089)	Aspergillosis	Other: No Intervention	Observational Model: Cohort Time Perspective: Prospective
47		A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants	Invasive Mucormycosis Invasive Aspergillosis	Drug: Isavuconazonium sulfate	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Children's Mercy Hospital Kansas City, Missouri, United States
48		Diagnostic and Management Strategies for InvasiveAspergillosis	Invasive Aspergillosis Neutropenia		Observational Model: Cohort Time Perspective: Prospective	King's College Hospital NHS Foundation Trust London, United Kingdom
49		Protocol TARC-ABPA	Allergic Broncho-Pulmonary Aspergillosis	Other: Study of predictive factors	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Diagnostic	CHU Le Mans Le Mans, France Nantes University Hospital Nantes, France
50		Isavuconazole in the Treatment of Renally ImpairedAspergillosis and Rare Fungi	Aspergillosis Invasive Fungal Infections	Drug: isavuconazole	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	University of Alabama at Birmingham Birmingham, Alabama, United States City Of Hope National Medical Center Duarte, California, United States University of California Davis Health System Sacramento, California, United States (and 94 more...)
51		To Determine Whether Galactomannan Test Will Help to Detect Fungal Infections Early and Hence Start Treatment Early	Aspergillosis	Behavioral: Galactomannan antigen monitoring, Aspergillus PCR Other: blood draws Other: blood draws for GM monitoring (and 3 more...)	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Diagnostic	Singapore General Hospital Singapore, Singapore
52		Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects	Aspergillosis Invasive Pulmonary Aspergillosis Neuroaspergillosis	Drug: Voriconazole Drug: Anidulafungin	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment
53		Invasive Pulmonary Aspergillosis Complicating Influenza Infection	Influenza With Pneumonia Aspergillosis Invasive		Observational Model: Case-Control Time Perspective: Prospective	AZ sint Jan Brugge, Belgium Jessa AH Hasselt, Belgium
54		Invasives Aspergillosis in Acute Myeloid Leukemia	Acute Myeloid Leukemia Invasive Aspergillosis	Other: Patients without antifungal prophylaxis Drug: Patients with antifungal prophylaxis	Observational Model: Cohort	CHRU de Brest Brest, France
55		Influenza Associated Aspergillosis In-depth Investigation	Influenza With Pneumonia Invasive Pulmonary Aspergillosis		Observational Model: Cohort Time Perspective: Prospective	Universitaire Ziekenhuizen Leuven Leuven, Belgium
56		Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic BronchopulmonaryAspergillosis	Cystic Fibrosis Allergic Bronchopulmonary Aspergillosis	Dietary Supplement: cholecalciferol (Vitamin D3)	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Comprehensive Lung Center - Falk Clinic Pittsburgh, Pennsylvania, United States Children's Hospital of Pittsburgh of UPMC Pittsburgh, Pennsylvania, United States
57		CYP 2C19 Polymorphism and Voriconazole Trough Concentration in Chinese Adult Patients	Invasive Pulmonary Aspergillosis	Drug: Voriconazole	Observational Model: Case-Only Time Perspective: Prospective	Qilu Hospital Jinan, Shandong, China
58		A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis	Allergic Bronchopulmonary Aspergillosis	Drug: Inhaled budesonide Drug: Inhaled amphotericin	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	Chest Clinic, PGIMER Chandigarh, India
59		Diagnostic Accuracy of Pleural Effusion AspergillosisBiomarker Testing	Invasive Aspergillosis Pleural Effusion Immunosuppression		Observational Model: Cohort Time Perspective: Prospective	University Hospital Mannheim Mannheim, Baden-Wuerrtemberg, Germany Wuerzburg University Hospital Wuerzburg, Bayern, Germany
60		Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis	Allergic Bronchopulmonary Aspergillosis	Drug: Glucocorticoids Drug: Itraconazole	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	Postgraduate Institute of Medical Education and Research Chandigarh, UT, India
61		An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute BronchopulmonaryAspergillosis (ABPA)	Cystic Fibrosis Allergic Bronchopulmonary Aspergillosis	Drug: Omalizumab Drug: Placebo Drug: Itraconazole	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment	Novartis Investigator Site Leuven, Belgium Novartis Investigator Site Berlin, Germany Novartis Investigator Site Bonn, Germany (and 7 more...)
62		Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation	Invasive Pulmonary Aspergillosis	Drug: Amphotericin B	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Participant) Primary Purpose: Prevention	Beijing Chaoyang Hospital,Affiliate of Capital Medical University Beijing, Beijing, China
63		Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease	Invasive Pulmonary Aspergillosis Chronic Obstructive Pulmonary Disease	Drug: caspofungin	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Guangzhou Institute of Respiratory Diseases Guangzhou, Guangdong, China
64		Diagnostic Performance of an Aspergillus-specific Nested PCR Assay in Cerebrospinal Fluid Samples	Focus: Immunocompromised Individuals at High Risk of Aqcuiring Invasive Aspergillosis		Observational Model: Cohort Time Perspective: Prospective	Freiburg University Hospital Freiburg, Baden-Würrtemberg, Germany Mannheim University Hospital Mannheim, Baden-Würrtemberg, Germany Frankfurt (Oder) General Hospital Frankfurt (Oder), Brandenburg, Germany
65		Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043)	Aspergillosis Candidiasis	Drug: caspofungin acetate	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment
66		A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945	Aspergillosis	Drug: PC945 - single doses Drug: Placebo - single doses Drug: PC945 - repeat doses Drug: Placebo - repeat doses	Allocation: Randomized Intervention Model: Crossover Assignment Masking: Single (Participant) Primary Purpose: Treatment	Parexel EPCU Harrow, Middlesex, United Kingdom
67		Surveillance of Fungal Infections During Construction Activity	Aspergillosis		Observational Model: Cohort Time Perspective: Prospective	Dept. Nephrology & Hypertension, Univ. Hospital Bern Bern, Switzerland
68		PCR Based Detection of Azole Resistance in A. Fumigatus to Improve Patient Outcome.	Aspergillosis, Invasive Pulmonary	Diagnostic Test: PCR based detection of azole resistance in A. fumigatus	Observational Model: Cohort Time Perspective: Prospective	Academisch Medisch Centrum Amsterdam, Netherlands VU Medisch Centrum Amsterdam, Netherlands Universitair Medisch Centrum Groningen Groningen, Netherlands (and 5 more...)
69		Evaluation of Performance of An Aspergillus PCR in Tissue and Pleural Effusion Samples of Immunocompromised Patients	Aspergillosis Immunosuppression		Observational Model: Cohort Time Perspective: Retrospective	Cologne University Hospital Cologne, Germany Duesseldorf University Hospital Duesseldorf, Germany Eschweiler General Hospital Eschweiler, Germany (and 9 more...)
70		Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects	Invasive Aspergillosis	Drug: F901318	Allocation: Randomized Intervention Model: Sequential Assignment Masking: None (Open Label) Primary Purpose: Other	Covance Clinical Research Unit Leeds, West Yorkshire, United Kingdom
71		Voriconazole for IPA in Chinese Patients With COPD	Invasive Pulmonary Aspergillosis COPD	Drug: Voriconazole	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Hangzhou Red Cross Hospital Hangzhou, Zhejiang, China
72		Drug/Drug Interactions With F901318	Invasive Aspergillosis	Drug: cyclosporine A Drug: Posaconazole Drug: Pantoprazole (and 2 more...)	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment
73		Pharmacokinetics of IV Formulation	Invasive Aspergillosis	Drug: F901318	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment
74		Radiolabelled IV and Oral Metabolism Study of F901318	Invasive Aspergillosis	Drug: IV F901318 Drug: Oral F901318	Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Other	Quotient Clinical Nottingham, Nottinghamshire, United Kingdom
75		Evaluation of Immediate Release Tablet	Invasive Aspergillosis	Drug: F901318 SDD Drug: F901318 IR Drug: F901318 IR Fasting Drug: F901318 IR Fed	Allocation: Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Quotient Clinical Nottingham, United Kingdom
76		Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects	Invasive Aspergillosis	Drug: F901318 Dose level A oral Drug: Placebo dose level A oral Drug: F901318 Dose level B oral (and 3 more...)	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment	Simbec Research Ltd Merthyr Tydfil, Glamorgan, United Kingdom
77		Study of Potential for Interaction of Fluconazole With F901318	Invasive Aspergillosis	Drug: F901318 Drug: Fluconazole	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	CELERION Belfast, Northern Ireland, United Kingdom
78		Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe	Invasive Aspergillosis	Drug: Midazolam with F901318	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Hammersmith Medicines Research London, United Kingdom
79		Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration	Invasive Aspergillosis	Drug: Voriconazole	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Other	Aarhus University Hospital Aarhus C, Denmark
80		Single Ascending Oral Dose Study of F901318	Invasive Aspergillosis	Drug: F901318 safety Drug: F901318 tolerability Drug: F901318 pharmacokinetics (and 3 more...)	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment	Simbec Orion Merthyr Tydfil, Wales, United Kingdom
81		F901318 Multiple Ascending Dose Study	Invasive Aspergillosis	Drug: F901318 Drug: Placebo	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment	Hammersmith Medicines Research London, UK, United Kingdom
82		Azole-resistance in Aspergillus	Pulmonary Aspergillosis		Observational Model: Other Time Perspective: Prospective	Division of Infectious Diseases and Hospital Epidemiology Basel, Switzerland
83		F901318 Single Ascending Dose Study in Healthy Male Volunteers	Invasive Aspergillosis	Drug: F901318 Drug: Placebo	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment	Simbec Research Merthyr Tydfil, Mid Glamorgan, United Kingdom
84		Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101)	Aspergillosis	Drug: Posaconazole Drug: Voriconazole	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment
85		Influence of Drug-drug Interactions on the Pharmacokinetics (PK) of Voriconazole	Invasive Aspergillosis	Drug: Voriconazole	Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label)	Seoul National University Hospital Clinical Trial Center Seoul, Korea, Republic of
86		Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis	Aspergillosis Invasive Fungal Infection	Drug: Isavuconazole Drug: Voriconazole	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment	University of Alabama Birmingham, Alabama, United States University of California at San Francisco San Francisco, California, United States University of Chicago, Division of Infectious Diseases Chicago, Illinois, United States (and 104 more...)
87		A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)	Candidiasis, Esophageal Candidiasis, Invasive Aspergillosis	Drug: Caspofungin	Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment
88		Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment	Invasive Aspergillosis Other Fungal Infections	Drug: AmBisome	Allocation: Randomized Intervention Model: Single Group Assignment Masking: Double Primary Purpose: Treatment
89		Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA	Cystic Fibrosis Allergic Bronchopulmonary Aspergillosis		Observational Model: Case Control Time Perspective: Prospective	Children's Hospital of Pittsburgh of UPMC Pittsburgh, Pennsylvania, United States
90		Voriconazole Prophylaxis Against Aspergillosis in Lung Transplant Recipients	Post Lung Transplantation		Observational Model: Case-Only Time Perspective: Prospective	University of Pittsburgh Medical Center Pittsburgh, Pennsylvania, United States
91		Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis	Immunocompromised Host Invasive Pulmonary Fungal Infection Invasive Pulmonary Aspergillosis Invasive Pulmonary Zygomycosis		Time Perspective: Prospective	Childrens National Medical Center Washington, D.C., District of Columbia, United States National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States
92		Diagnosis of Invasive Pulmonary Aspergillosis (IPA) in Critically Ill Patients	Survival After IPA Risk Factors for IPA		Observational Model: Case-Only Time Perspective: Prospective	University Medical Center Hamburg-Eppendorf Hamburg, Germany
93		Cytokine Profile of Allergic BronchopulmonaryAspergillosis	ABPA		Observational Model: Cohort Time Perspective: Prospective	Shanghai Pulmonary Hospital Shanghai, Shanghai, China
94		Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia	Invasive Pulmonary Aspergillosis Lymphoblastic Leukaemia Myeloblastic Leukaemia (and 2 more...)	Drug: AMPHOTERICIN B	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Hospital Sant Joan de Déu Esplugues de Llobregat, Barcelona, Spain
95		Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis	Infection Pulmonary Complications	Drug: amphotericin B deoxycholate Drug: voriconazole	Allocation: Randomized Primary Purpose: Supportive Care	Hartford Medical Group Wethersfield, Connecticut, United States St. Vincent's Hospital Sydney, New South Wales, Australia Royal Brisbane Hospital Brisbane, Queensland, Australia (and 71 more...)
96		Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To Less Than 15 Years Old Who Are At High Risk For Systemic Fungal Infection	Aspergillosis, Aspergilloma	Drug: Voriconazole	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Prevention	Japanese Red Cross Nagoya Daiichi Hospital Nagoya, Aichi, Japan National hospital Organization Nagoya Medical Center Nagoya, Aichi, Japan Sapporo Hokuyu Hosipital Sapporo, Hokkaido, Japan (and 3 more...)
97		Radiologic Features of Invasive PulmonaryAspergillosis	Hematologic Disease Solid Organ Transplantation		Observational Model: Cohort Time Perspective: Retrospective
98		Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant	Cancer	Drug: caspofungin acetate	Masking: None (Open Label) Primary Purpose: Supportive Care	CHU Liege - Domaine Universitaire du Sart Tilman Liege, Belgium Centre Hospitalier Universitaire Henri Mondor Creteil, France Hopital Edouard Herriot - Lyon Lyon, France (and 10 more...)
99		Role of Thymus-And Activation-Regulated Chemokine (TARC) In Diagnosis Of Allergic BronchopulmonaryAspergillosis	Thymus and Activation Regulated Chemokine		Observational Model: Cohort Time Perspective: Prospective
100		A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of InvasiveAspergillosis (MK-5592-069)	Fungal Infections	Drug: Posaconazole Drug: Voriconazole	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment	Call for Information (Investigational Site 0010) Birmingham, Alabama, United States Call for Information (Investigational Site 0127) Chicago, Illinois, United States Call for Information (Investigational Site 0250) Boston, Massachusetts, United States (and 26 more...)